Fulvestrant as First-Line Treatment for Advanced Breast Cancer

Clinical Pearls

John F. R. Robertson, MD, professor of surgery, faculty of medicine & health sciences, The University of Nottingham, United Kingdom, discusses overall survival data from the phase II FIRST study, which looked at fulvestrant as first-line therapy for patients with advanced breast cancer.

• 20-25 years ago, the average survival among patients with advanced breast cancer was 24 months. Now, it is 54.1 months.
• Overall survival was 5.7 months higher with fulvestrant compared with anastrozole.
• Benefit for fulvestrant over anastrozole was consistent across subgroups.

<<<

Go back to the SABCS conference page